Canagliflozin With Gemcitabine in Pancreatic Carcinoma
Status:
Not yet recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
Gemcitabine-based chemotherapy or combination with FOLFIRINOX is the leading treatment of
pancreatic cancer. However, the overall response rate of pancreatic cancer to gemcitabine is
less than 20%. Resistance to gemcitabine is the most important reason. There is an urgent
need to develop new combination therapies to improve the efficiency of chemotherapy, avoid
toxicity limitations, and improve the overall prognosis of pancreatic cancer. At present, it
has been found that canagliflozin can reduce the expression level of PD-L1 in pancreatic
cancer and restore the vitality of CD8+ T cells. Canagliflozin combined with gemcitabine may
improve the efficiency of chemotherapy.
Phase:
N/A
Details
Lead Sponsor:
Zhang Xiaofeng,MD
Collaborators:
College of Pharmaceutical Sciences at Zhejiang University The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University